Epigral Q1FY27: Revenue up 15% to ₹709 Cr, PAT surges 25% to ₹99 Cr; Approves new capex
Epigral reported Q1FY27 revenue of ₹709 Crore, up 15% YoY, with PAT at ₹99 Crore, up 25% YoY. EBITDA grew 10% to ₹179 Crore. The company's board approved capex for a 1,25,000 TPA Epoxy Resin & Formulations plant and a Multi-Purpose Plant, expected by H2FY28. Enhancements to CPVC Resin and ECH capacities are also on track.
The announcement includes strong financial performance and significant new capital expenditure plans for capacity expansion, which are material events for the company's future growth and market position.
The company reported strong year-on-year growth in revenue and profit, along with positive commentary from the CMD and strategic investments in new capacity, indicating a favorable outlook.
Epigral Limited announced its un-audited financial results for the first quarter of Fiscal Year 2027 (Q1FY27), reporting a 15% year-on-year growth in revenue to ₹709 Crore. This growth was driven by a 5% increase in sales volume and improved realisations. The company's absolute EBITDA grew by 10% to ₹179 Crore from ₹163 Crore in Q1FY26, maintaining an EBITDA margin of 25%. Profit After Tax (PAT) saw a significant jump of 25%, reaching ₹99 Crore compared to ₹79 Crore in the same quarter last year, with a PAT margin of 14%.
During the quarter, Epigral's board approved significant capital expenditure for two new projects: an Epoxy Resin & Formulations plant with a capacity of 1,25,000 TPA and a Multi-Purpose Plant (MPP) for downstream Epichlorohydrin (ECH) and Chlorotoluene Value Chain. Both projects are expected to be commissioned by the second half of FY28. The company is also setting up pilot plants for these projects to optimise manufacturing processes and validate product quality. Additionally, capex for enhancing CPVC Resin and ECH capacity, along with a Wind Solar Hybrid Power Plant, are progressing as per schedule and expected to be commissioned within timelines and budget.
Chairman and Managing Director, Mr. Maulik Patel, highlighted that despite macroeconomic volatility and supply chain challenges, Epigral achieved steady growth by leveraging its diversified product mix. He expressed a positive outlook, supported by India's economic growth, and emphasized the strategic importance of the new capex in enhancing efficiency and diversifying the portfolio to deliver long-term stakeholder value. The Epoxy Resin plant will cater to growing domestic and global demand, while the MPP will address the rising demand for pharmaceutical and agrochemical intermediates.
What to do with a filing like this
Epigral Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Epigral Limited. Read the original for the full detail.